ArticleBMB reports2025
LPS stimulation-induced regulation of LECT2 expression via TLR4 in hepatocytes.
Article in BMB reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nuclear Galectin-1 Drives Cancer Progression throughInternational journal of biological sciences · 2026Article
- Pharmacological inhibition of Ubiquitin-Specific Peptidase 10 (USP10) with spautin-1 attenuates adipogenesis through CCAAT/Enhancer-Binding Protein Beta (C/EBPβ) destabilization.Molecular biomedicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leukocyte cell-derived chemotaxin 2 (LECT2), a secreted protein, is implicated in various physiological and pathological processes. As a hepatokine, LECT2 is predominantly synthesized and secreted by hepatocytes, with elevated levels being associated with multiple human inflammatory diseases. Although LECT2 plays a critical role in liver and systemic inflammation, the intracellular signaling mechanisms governing its expression under inflammatory conditions remain unclear. This study demonstrates that lipopolysaccharide (LPS) directly induces LECT2 expression in AML12 mouse hepatocytes. Use of a TLR4-specific inhibitor confirmed that LPS-induced LECT2 expression is mediated via its canonical receptor, TLR4. Furthermore, the p38 MAPK pathway was identified as a key mediator of this response, as evidenced by pharmacological modulation with a p38-specific inhibitor and agonist. Promoter analysis of the Lect2 gene revealed the presence of a putative AP-1-like binding site, suggesting transcriptional regulation by AP-1. Overexpression of c-Fos and c-Jun, along with ChIP-qPCR analysis, confirmed that AP-1 directly binds to Lect2 promoter, and regulates its transcription in response to LPS. Together, these findings reveal a novel TLR4/p38 MAPK/AP-1 signaling axis that, during inflammation, regulates LECT2 expression in hepatocytes, providing new insights into the molecular mechanisms underlying liver inflammation and LECT2-mediated pathophysiology. [BMB Reports 2025; 58(6): 250-256].
Indexed as
Identifiers
40495481PMC12207439What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.